γδ T cells infiltrate small cell lung cancer tumors and can kill them without the MHC-I machinery these tumors typically switch off, and patients with more of them trended toward longer survival on anti-PD-L1 immunotherapy.
|Videos|October 19, 2021
- MHE October 2021
- Volume 31
- Issue 10
Rachel Kotok Goldberg Shares Developing Evidence-Based Behavioral Health Programs for Horizon Has Been a Great Career Accomplishment
Author(s)Briana Contreras
Rachel Goldberg, B.S.N, RN, director of behavioral health client partnerships and product innovation at Horizon Blue Cross Blue Shield of New Jersey, is one of the emerging health leaders featured in the October 2021 issue of Managed Healthcare Executive. In this video she talks about the career achievement that has given her the greatest satisfaction and who has had the greatest influence on her life.
Advertisement
Articles in this issue
about 5 years ago
Emerging Health Leaders: Sonia Samagh of Stealth Ventureabout 5 years ago
Emerging Health Leaders: Andrew Toy, M.S., of Clover Healthabout 5 years ago
Emerging Health Leaders: Evie Powell, Ph.D., of Proprioabout 5 years ago
Emerging Health Leaders: Michael Palantoni of AthenahealthAdvertisement
Related to this article
Upstream payment accuracy should reduce avoidable noise before it reaches those downstream functions.
The results come several months after the FDA approved Lisraya for dermatomyositis.
Psychedelic therapies are nearing FDA decisions, but people with HIV, many covered by Medicaid, have been left out of nearly all trials, commentary authors argue.
Christopher Stanley, M.D., MBA, says Henry Ford Health now projects its 2027 employee healthcare insurance premiums to increase half as much as what had been expected, partly because of Populance’s to bring about cost-effective care.
Rybrevant Faspro won accelerated approval for recurrent or metastatic HNSCC after a trial showed a 42% response rate in previously treated patients.
David Feldshon, M.D., a Yale gastroenterologist who still performs endoscopy two days a week at 75, discusses his approach to MASLD and life outside the clinic.
Researchers in Lyon, France, conducted a retrospective cohort study of intensifying the dosing of biologics such as Humira, adding oral antibiotics, or both as ways to boost the response of patients with hidradenitis suppurativa.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Calibrating biologic treatment of HS to the response patterns to biologics
2
Quick Q&A: Christopher Stanley, M.D., MBA, on population health and healthcare affordability
3
After a 10-year gap, FDA approves new option for pretreated head and neck cancer
4
As psychedelic drugs near FDA decisions, people with HIV remain absent from trials, commentary says
5